ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 564,04
-0,59%
Dow Jones
39 211,33
0,21%
DAX
18 228,97
0,36%
Brent Oil
85,255
0,93%
Bitcoin
61 613,24
1,32%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Fractyl Health Inc (GUTS)

  7. Fractyl Health Inc (GUTS) Actualités

GUTS

Fractyl Health (GUTS)

Fractyl Health Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:GUTS
DateHeureSourceTitreSymboleSociété
25/06/202413h00GlobeNewswire Inc.Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity DayNASDAQ:GUTSFractyl Health Inc
24/06/202412h00GlobeNewswire Inc.Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business UpdatesNASDAQ:GUTSFractyl Health Inc
29/05/202413h00GlobeNewswire Inc.Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific SessionsNASDAQ:GUTSFractyl Health Inc
20/05/202412h00GlobeNewswire Inc.Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024NASDAQ:GUTSFractyl Health Inc
14/05/202422h15Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:GUTSFractyl Health Inc
13/05/202422h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GUTSFractyl Health Inc
13/05/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GUTSFractyl Health Inc
13/05/202422h00GlobeNewswire Inc.Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:GUTSFractyl Health Inc
13/05/202412h00GlobeNewswire Inc.Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)NASDAQ:GUTSFractyl Health Inc
08/05/202412h00GlobeNewswire Inc.Fractyl Health to Present at BofA Securities 2024 Health Care ConferenceNASDAQ:GUTSFractyl Health Inc
07/05/202412h00GlobeNewswire Inc.Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024NASDAQ:GUTSFractyl Health Inc
30/04/202414h38GlobeNewswire Inc.Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual MeetingNASDAQ:GUTSFractyl Health Inc
02/04/202414h00GlobeNewswire Inc.Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 DiabetesNASDAQ:GUTSFractyl Health Inc
01/04/202413h00GlobeNewswire Inc.Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:GUTSFractyl Health Inc
01/04/202412h00GlobeNewswire Inc.Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based DrugsNASDAQ:GUTSFractyl Health Inc
12/03/202419h06GlobeNewswire Inc.UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and ObesityNASDAQ:GUTSFractyl Health Inc
12/03/202413h38GlobeNewswire Inc.Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and ObesityNASDAQ:GUTSFractyl Health Inc
20/02/202414h38GlobeNewswire Inc.Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical TrialsNASDAQ:GUTSFractyl Health Inc
02/02/202402h08GlobeNewswire Inc.Fractyl Health Announces Pricing of Initial Public OfferingNASDAQ:GUTSFractyl Health Inc
 Showing the most relevant articles for your search:NASDAQ:GUTS

Dernières Valeurs Consultées

TG
A13R8W
KFW
COIN
GROWBTC
LSE
A2D1
A2d Fund. 22
LSE
10OY
Anz Bank 43
TG
A3LF6E
Securitas Treasury Ireland
NYSE
JZH
NYSE
GIK.U
GigCapital3
TG
BP45YQ
BNP Paribas Home Loan SFH
COIN
BORAUSD
BORA
AMEX
DTRE
First Trust Alerian Disr...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés